Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M; GICNO. Brandes AA, et al. Among authors: ermani m. J Clin Oncol. 2006 Oct 10;24(29):4746-53. doi: 10.1200/JCO.2006.06.3891. Epub 2006 Sep 5. J Clin Oncol. 2006. PMID: 16954518 Clinical Trial.
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M. Brandes AA, et al. Among authors: ermani m. J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163. J Clin Oncol. 2008. PMID: 18445844
O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.
Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, Calbucci F, Ermani M. Brandes AA, et al. Among authors: ermani m. Neuro Oncol. 2010 Mar;12(3):283-8. doi: 10.1093/neuonc/nop050. Epub 2010 Feb 1. Neuro Oncol. 2010. PMID: 20167816 Free PMC article.
Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications.
Brandes AA, Franceschi E, Paccapelo A, Tallini G, De Biase D, Ghimenton C, Danieli D, Zunarelli E, Lanza G, Silini EM, Sturiale C, Volpin L, Servadei F, Talacchi A, Fioravanti A, Pia Foschini M, Bartolini S, Pession A, Ermani M. Brandes AA, et al. Among authors: ermani m. Oncologist. 2017 Apr;22(4):432-437. doi: 10.1634/theoncologist.2016-0254. Epub 2017 Mar 8. Oncologist. 2017. PMID: 28275120 Free PMC article.
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crinò L, Ermani M; GICNO. Brandes AA, et al. Among authors: ermani m. Br J Cancer. 2006 Nov 6;95(9):1155-60. doi: 10.1038/sj.bjc.6603376. Epub 2006 Oct 3. Br J Cancer. 2006. PMID: 17024124 Free PMC article. Clinical Trial.
Post progression survival in glioblastoma: where are we?
Franceschi E, Ermani M, Bartolini S, Bartolotti M, Poggi R, Tallini G, Marucci G, Fioravanti A, Tosoni A, Agati R, Bacci A, Pozzati E, Morandi L, Balestrini D, Ghimenton C, Crisi G, Brandes AA. Franceschi E, et al. Among authors: ermani m. J Neurooncol. 2015 Jan;121(2):399-404. doi: 10.1007/s11060-014-1651-7. Epub 2014 Nov 1. J Neurooncol. 2015. PMID: 25366365
227 results